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Abstract
Background: Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading
to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvement who
received Everolimus had a delayed tumor progression in the skeleton as a result of direct OC suppression through
the inhibition of mTOR, in addition to the general suppressor effect on the cancer cells. Here, we explored the
effect of Everolimus, as mTOR inhibitor, on the pro-OC paracrine activity of BC cells.
Methods: Both MDA-MB-231 and MCF-7 BC cell lines were incubated with sub-lethal amounts of Everolimus, and
their conditioned supernatants were assessed for their capacity to differentiate OCs from PBMC from healthy
donors, as well as to interfere with their bone resorbing activity shown on calcium phosphate slices. We also
measured the mRNA levels of major pro-OC factors in Everolimus-treated BC cells and their secreted levels by
ELISA, and evaluated by immunoblotting the phosphorylation of transcription factors enrolled by pathways
cooperating with the mTOR inhibition. Finally, the in vivo pro-OC activity of these cells was assessed in SCID
mice after intra-tibial injections.
Results: We found that Everolimus significantly inhibited the differentiation of OCs and their in vitro bone-resorbing
activity, and also found decreases of both mRNA and secreted pro-OC factors such as M-CSF, IL-6, and IL-1β, whose
lower ELISA levels paralleled the defective phosphorylation of NFkB pathway effectors. Moreover, when intra-tibially
injected in SCID mice, Everolimus-treated BC cells produced smaller bone metastases than the untreated cells.
Conclusions: mTOR inhibition in BC cells leads to a suppression of their paracrine pro-OC activity by interfering
with the NFkB pathway; this effect may also account for the delayed progression of bone metastatic disease
observed in the BOLERO-2 trial.
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Background
The development of skeletal metastases, leading to hy-
percalcemia, fractures, and vertebral collapse with spinal
compression and intractable pain, is a major cause of
morbidity in patients with advanced breast cancer (BC)
[1]. Their formation is primarily induced by a marrow
environment fostering tumor growth, thanks to the
functional cross-talk between BC cells and resident cells
such as hematopoietic progenitors, stromal, endothelial
and other marrow components [2]. Although a direct
bone resorption activity by BC cells was postulated [3],
it is currently believed that osteolytic lesions are pro-
duced by marrow osteoclasts (OC), whose differentiation
from myeloid precursors is accelerated by the tumor
cells [4]. BC cells secrete PTHrP (parathormone-related
protein) [5], in addition to other soluble factors that are
normally secreted by stromal and other marrow cells to
regulate the OC maturation, and have M-CSF (macro-
phage-colony stimulating factor), IL (interleukin)-1β, IL-8,
IL-6 and TNF-α (tumor necrosis factor) functions [6–8].
Specific signatures of molecular pathways in BC cells
have been associated with a highly malignant phenotype
[9] and worse clinical outcome [10]. For instance, hyper-
activity of the phosphoinositide 3-kinase (PI3K)/Protein
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Kinase B (Akt)/mammalian target of Rapamycin (mTOR)
pathway, is a molecular hallmark of accelerated prolifera-
tion and tumor progression in BC cells, since intrinsic
molecular aberrations recur in approximately 40 % of pa-
tients with metastatic skeleton disease [11]. The constitu-
tive phosphorylation of Akt, as well as mutations of the
catalytic subunit of PI3K (PIK3CA), result in persistent ac-
tivation of mTOR as the downstream serine/threonine
kinase that primarily regulates proliferation, survival
and apoptosis in BC cells [12]. Further work also sug-
gests that this abnormal mTOR activity induces a pe-
culiar osteotropic phenotype of BC cells, probably
involved in skeleton colonization [13], that could ul-
timately be modulated by inhibiting this pathway, as
demonstrated in other cancers [14].
Based on the results of the BOLERO-2 trial, the mTOR
inhibitor Everolimus (RAD001) has been approved for use
in postmenopausal women with hormone-receptor positive
(HR+)/Her-2− advanced BC, refractory to non-steroidal
aromatase inhibitors [15]. In this study, a beneficial effect
on bone health was documented in bone-metastatic pa-
tients receiving the drug, skeletal tumor progression being
significantly delayed as compared to in the control group
patients [16]. The bone resorption markers at 6 and
12 weeks revealed a significant decrease in patients treated
with Everolimus [16], and this beneficial effect on bone
health was attributed to the reduced OC function associ-
ated to the general anti-tumor activity induced by Everoli-
mus on BC cells, as well as to a direct mTOR inhibition in
BC-stimulated OCs, since this pathway drives their func-
tional maturation [17]. However, this result in the
BOLERO-2 trial may also be explained as an effect of sup-
pressed pro-OC paracrine activity of BC cells in response
to the mTOR inhibition, besides its modulatory role on
hyperactive OCs. Another trial, the RADAR study, sug-
gested that Everolimus as a single agent was beneficial in
patients showing only bone involvement [18]. These effects
have been further emphasized in a recent subanalysis of
the BOLERO-2 trial confirming the beneficial effect of
Everolimus in the sub-population of BC patients with bone
metastases, as well as in other subgroups [19].
However, in OC progenitors, as in BC cells, the secre-
tion of pro-OC factors is independent of the mTOR
pathway since the nuclear factor kappa B (NFkB) path-
way is primarily involved through transcriptional factors
regulating their release and activity [20–24]. Therefore,
assuming that mTOR inhibition restrains the whole
tumor activity in BC cells, as described in BOLERO-2, it
is conceivable that both the mTOR and NFkB pathways
may be molecularly interconnected and that their inter-
action may ultimately bring about the inhibitory effect
on the secretion of pro-OC factors [25].
Here, we investigated the potential of Everolimus to
regulate the pro-OC paracrine activity of BC cells, and
provide evidence that this mTOR inhibitor restrains the
bone-destroying potential of BC cells both in vitro and
in vivo, through a synergic negative efficacy on both
mTOR and NFkB. Thus, the NFkB-mediated suppres-
sion of the pro-OC paracrine activity by BC cells in pa-
tients enrolled in the BOLERO-2 trial may account for
the beneficial bone effect attributed to Everolimus.
Methods
Compound
Everolimus [40-O-(2-hydroxyethyl)-rapamycin]) as pure
extract powder was provided by Novartis Pharma and
prepared in dymethylsulfoxide, diluted at 100 mg/ml, for
in vitro use.
BC cell lines and survival assay
MDA-MB-231 and MCF-7 BC cells (ATCC, Rockville,
MD, USA) were cultured in RPMI 1640 supplemented
with 10 % FCS (Sigma Aldrich, Milan Italy), 100 U/ml
penicillin/streptomycin and 2 mM L-glutamine (PAA,
Pasching, Austria) in 5 % CO2-incubator. Both cell lines
were incubated for 48 h with increasing concentrations
(10−1 to 104 nM) of Everolimus and their viability was
assessed by methylene blue. Briefly, after fixation with
glutharaldehyde, the cells were incubated for 10 min
with methylene blue [0.05 % (w/v) in water], then treated
with HCl [3 % (v/v)] and read at 650 nM of absorbance
in a microtiter reader (BIO-Rad, Milan, Italy). The in-
hibitory concentration 20 (IC20), defined as the amount
of Everolimus able to reduce cell growth by 20 %, was
calculated according to BioDataFit 1.02 software by
interpolation of the dose-response curves. IC20 was ar-
bitrarily used as the sub-lethal dose and each experiment
was performed in triplicate.
BC cell conditioned media (CM)
After 48 hr-treatment with control DMSO or Everolimus
at IC20, BC cells (1 × 10
5/well) were seeded in 6-well
plates for 24 h. Then, supernatants were recovered, fil-
tered, frozen at −20 ° C until use for in vitro and in vivo
experiments (see below).
OC differentiation and activity
Human OCs were obtained from the peripheral blood of
healthy blood donors, after obtaining written informed
consent, and approval by the Ethics Committee of the
University of Bari. OCs were generated in vitro after 16-
day incubation of PBMCs with RANKL (50 ng/ml) and
M-CSF (25 ng/ml) (Isokine, Iceland), as previously re-
ported [26]. At day 8, PBMCs were supplemented with
20 % of CM from DMSO- or Everolimus-treated cells
and after a further 8 days of incubation, both the morph-
ology and function of OCs were assessed.
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We arbitrarily considered as OC-like cells, polykaryons
with at least three nuclei, that were counted in ten micro-
scopic fields at 30× magnification after hematoxylin-eosin
staining (Vector Labs, Sigma) and compared with tartrate-
resistant acid phosphatase positive (TRAcP+) cells in par-
allel preparations using naphthol AS-BI 0.12 mg/ml,
6.76 mM tartrate, and 0.14 mg/ml Fast Garnet GBC
(Sigma-Aldrich).
Functional OC activity was measured on experimental
bone substrate. Briefly, pre-OCs obtained after 8 days of
culture in the presence of RANKL and M-CSF were in-
cubated for a further 8 days with and without CM on
calcium phosphate discs (BioCoat Osteologic Discs; BD
Biosciences). Then, the cells were removed by 5 % so-
dium hypochlorite and the substrates were stained by
the Von Kossa method to reveal erosive pits. We also
quantified both the number of pits and the percentage
of the resorbed area by a dedicated software (Olympus)
under light microscopy.
RT-PCR
After 48 hr-treatment with control DMSO or Everolimus
at IC20, both the MDA-MB-231 and MCF-7 cell lines
were measured for mRNA levels of M-CSF, RANKL,
TNF-α, IL1-β, IL6, MMP (metalloproteinase)-9, MMP-
13, MCP (monocyte chemoattractant protein)-1, MIP
(macrophage inflammatory protein)-1α, as the major
pro-OC factors [27–32]. Also, the OC-like phenotype of
BC cells was assessed on the levels of TRAcP, cathepsin
K (Cat K) and c-fms. RNAs were extracted by the RNeasy
kit (Qiagen, Chatsworth, CA) and the relative concentra-
tions calculated by a Bio Photometer (Eppendorf) at
260 nm. After evaluating RNA integrity by electrophor-
esis, cDNA was obtained by reverse transcription of 1 μg
of total RNA using a commercial kit (Applied Biosystems,
Milan) in a Mastercycler Personal (Eppendorf). Levels of
the above genes were assessed by specific primers
(Additional file 1: Table S1) designed on different exons to
avoid amplification of contaminating genomic DNA.
β-actin was selected as target gene for the RT-PCR
using Sybr Green (Maxima® SYBR Green/ROX qPCR
Master Mix, Fermentas), in the ABI Prism 7300 Se-
quence Detector (Applied Biosystems). Following an
initial incubation at 50 °C for 2 min, samples were
denatured at 95 °C for 10 min, then by 40 cycles at
95 °C for 15 s, and 1 min at 60 °C. All tests were
completed in triplicate and gene expression levels
were obtained as 2-ΔΔCt [33].
Measurement of pro-OC cytokines released by BC cells
M-CSF, IL1-β, IL-6, TNF-α and MIP-1α were measured in
CM from each cell preparation by the appropriate ELISA
(R&D systems, Minneapolis, MN), as reported [34].
Immunoblotting assessment of the mTOR and NFkB
pathways in BC cells
Both DMSO- and Everolimus-treated MDA-MB-231
and MCF-7 cells were investigated for activation of the
mTOR and NFkB pathways, as well as for the produc-
tion of NFkB-dependent pro-OC mediators. After 48 hr-
incubation, cells were harvested and lysed in mRIPA
lysis buffer (10 mM Tris–HCl, 150 mM NaCl, 2 mM
EDTA, 1 % NP40, 0.1 % 0.1 % SDS, 1 % sodium deoxy-
cholate) and 20 μg of total protein lysate were resolved
on 10 % SDS-PAGE and subjected to Western-blotting
[35] using MoAbs to Akt, phosphorylated (p)-mTOR, p-
p70S6K (Millipore, Billerica, MA, USA), IKKα, p-IKKα,
p65, p-p65, as well as M-CSF, IL-1β, IL-6 (Cell Signaling
Technology, Danvers), TNF-α and MIP-1α (Abcam,
Cambridge). β-actin was used as intra-assay marker for
both quality and quantity loading of sample lysates.
Generation and detection of BC bone metastases in vivo
To investigate the capability of BC cells to generate in
vivo bone metastases and the effect of the 48 hr-treat-
ment with sub-lethal doses of Everolimus, we utilized
MDA-MB-231 as predominant bone metastasizing BC
cell model [36] in 8-week old NOD.CB17-Prkdcscid/J
mice (Charles River, Milan, I). All experiments were per-
formed in accordance with the Italian Guidelines for the
use of laboratory animals, following the European Union
Directive for the protection of experimental animals
(2010/63/EU), after receiving approval from the Animal
Experimentation Ethics Committee (CESA) of University
of Bari “Aldo Moro”. Animals were maintained under
standard environmental conditions and provided with
feed and water ad libitum. Considering the animal eth-
ical issues, all animals were kept under best hygienic
conditions and were daily inspected for signs of pain or
discomfort. Briefly, eight mice were anesthetized by Iso-
fluorane, and 1 × 105cells/20 μl of Everolimus-treated
and untreated MDA-MB-231 were inoculated into the
left and the right tibial cavity, respectively, of the flexed
knees of each animal. After 4 weeks, the animals were
euthanized by carbon dioxide and X-Rays were taken at
20 kV and 25 mAs for 5 s using a mammographic device
(Model Flat E; Metaltronica, Rome). Films were then
comparatively inspected for structural deformities and
the size of visible tibial lesions was measured by ImageJ
software, version 1.45 (National Institutes of Health,
Bethesda, MD). The extent of osteolytic areas, as mm2
of bone devastation, were compared in each mouse be-
tween the right and left tibias.
Bone immunohistochemistry
The tibias were excised, fixed and decalcified in EDTA
for paraffin-embedding; 4 μm-thick sections were
stained with hematoxylin-eosin while parallel sections
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were prepared for TRAcP staining (Aviva Systems Biology,
San Diego) using specific reagents and avidin-biotin
(Vector Labs, Burlingame) to reveal TRAcP+ cells [37].
Statistical analysis
We employed GraphPad Prism 6.1 software (Macintosh,
La Jolla, CA) and differences were calculated by Student’s
t test. P < 0.05 was considered statistically significant.
Results
Everolimus sub-lethal dose
We firstly assessed the cytotoxic activity of Everolimus
on BC cells (Additional file 1: Figure S1). The IC20 con-
centration of Everolimus was 10 nM for MDA-MB-231
cells and 0.5 nM for MCF-7 cells; these were used as
sub-lethal doses.
BC-induced osteoclastogenesis is restrained by
Everolimus
Figure 1a shows the pro-OC potential of CM from both
BC cell lines, as untreated and Everolimus-treated cells.
CM from both untreated cell lines produced higher num-
bers of polykaryons (MDA-MB-231: 32.5 ± 1.5; MCF-7:
45 ± 6 cells/field) compared to control PBMCs (16 ± 1
cells/field; p < 0.05), whereas CM from Everolimus-treated
MDA-MB-231 and MCF-7 significantly reduced the poly-
karyon generation, to 35 % (21 ± 2.6 cells/field) and 23 %
(35 ± 4 cells/field), respectively (p < 0.05). We further in-
vestigated the TRAcP expression in polykaryons (Fig. 1b).
Again, the number of TRAcP+ cells was enhanced by CM
from both BC cell lines (MDA-MB-231: 35 ± 2.5; MCF-7:
43 ± 2 cells/field) as compared to control PBMC prepara-
tions (22 ± 2.5 cells/field; p < 0.05), while this effect was
neutralized by CM from both Everolimus-treated cell lines
(p < 0.05). The bottom images of Fig. 1b illustrate basal
TRAcP+ cell formation (left), after MCF-7 CM (middle),
and CM from Everolimus-treated MCF-7 cells (right).
Everolimus restrains the BC-mediated OC hyperactivity
The restraining effect of Everolimus on the pro-OC ac-
tivity of BC cells was investigated at both RNA and func-
tional levels.
As shown in Fig. 2, quantitative RT-PCR revealed that
OCs had significantly increased mRNA levels of TRAcP,
Cat-K and c-fms after incubation with CM from both
the MDA-MB-231 and MCF-7 cell lines (p < 0.05). No
variation was observed for RANK mRNA after adding
MDA-MB-231 CM, whereas treatment with CM from
Everolimus-treated BC cells resulted in a suppression of
TRAcP, Cat-K and c-fms (p < 0.05). Functional tests sup-
ported these results. OCs showed a dramatically rein-
forced bone resorbing activity on calcium-phosphate
slices after adding CM from both BC cell lines and, con-
trarily, a significantly inhibited activity when using CM
from Everolimus-treated cells (Fig. 3). In particular,
Fig. 3a (above) shows that OCs stimulated with CM pro-
duced higher numbers of erosion pits (MB-231: 45 ± 2.5;
MCF-7: 32 ± 3) than control OCs (20 ± 3.1), with in-
creased total resorbed areas, equal to 3.8 and 3.1 %, re-
spectively, with CM from untreated MDA-MB-231 and
MCF7 cells, compared to 1.5 % of the control OCs, as
shown in Fig. 3a (below). By contrast, when using CM
from Everolimus-treated BC cells, both erosion pits and
resorbed areas were significantly reduced (p < 0.05 in all
instances). Figure 3b depicts representative images of
erosion pits on calcium-phosphate discs. These results
emphasized the ability of Everolimus to restrain the BC-
mediated hyperactivity of OCs, at both molecular and
functional levels.
Everolimus restrains the pro-OC paracrine activity of BC
cells
MDA-MB-231 and MCF-7 were tested by RT-PCR for
M-CSF, RANKL, TNF-α, IL-1β, IL-6, MMP-9, MMP-13,
MCP-1 and MIP-1α, before and after Everolimus treat-
ment. Levels of mRNAs were normalized to 1.0 as 2-ΔΔct
basal value and with the exception of RANKL, MMP-9
and MCP-1α, that were almost undetectable (data not
shown), both cell lines showed a variably suppressed
RNA transcription of the other genes after Everolimus
treatment. Results are illustrated in Fig. 4a. MDA-MB-
231 cells underwent significant reductions (p < 0.02) of
M-CSF, TNF-α, and MMP-13 RNA levels whereas IL-6
was unaffected (p > 0.05), like IL-1β and MIP-1α. In par-
allel, MCF-7 cells were suppressed by Everolimus in IL-
1β, IL-6, MIP-1α and MMP-13 (p < 0.02 in all instances),
unlike M-CSF and TNFα.
To verify whether the suppressed transcription of
RNAs was paralleled by a concurrent reduction in the
secretion of related proteins, we measured M-CSF,
TNFα, IL-1β, IL-6, MIP-1α, and MMP-13 amounts in
CM by ELISA. Figure 4b depicts the results, showing an
apparent correlation of RNA amounts with lower se-
creted levels of those cytokines. MDA-MB-231 cells con-
stitutively secreted consistent amounts of both M-CSF
and TNF-α, whereas MCF-7 cells produced higher levels
of IL-1β, IL-6 and MIP-1α than MDA-MB-231. How-
ever, Everolimus significantly inhibited this paracrine ac-
tivity in both cell lines (p < 0.05 in all instances).
mTOR inhibition by Everolimus disables NFkB signaling in
BC cells
Since the NFkB pathway regulates the transcription of
M-CSF, IL-1β, IL-6, TNFα and MIP-1α for the relative
protein secretion by BC cells, we investigated the inter-
ference exerted by Everolimus on mTOR and NFkB sig-
naling. By Western-blot, we measured the amounts of
major factors of both pathways, such as Akt,
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phosphorylated (p) mTOR, p-p70S6K, IKKα, p-IKKα,
p65, and p-p65, in both BC cell lines before and after
Everolimus treatment. Figure 5 (up) depicts the constitu-
tively increased expression of p-mTOR and its down-
stream effector p-p70S6K in both cell lines, although at
higher levels in MCF-7 (OD values are in, Additional file
1: Table S2). As expected, Everolimus decreased p-
mTOR and p-p70S6K levels in both cell lines,
particularly in MCF-7 cells, whereas no change in
Akt expression was observed, confirming the ability
Fig. 1 Osteoclastogenic potential of BC cells and effects of Everolimus. PBMCs from healthy donors were differentiated to OCs using osteoclastogenic
factors (left) and conditioned medium (CM) from MDA-MB-231 and MCF-7 BC cell lines, before (middle) and after (right) treatment with Everolimus. The
pro-OC potential was measured as numbers of both large multinucleated OC-like cells stained by hematoxylin/eosin (a) and multinucleated TRAcP+
cells (b). CM from BC cells produced significant increases (*p < 0.05) of OC formation, although the greatest effect was with MCF-7 cells (middle). Both
constitutive and BC-mediated osteoclastogenesis were abrogated when using CM from BC cells pretreated with a sub-lethal dose of Everolimus.
The pattern of increased/reduced OC formation was similarly evident after different staining. a bottom: Polykaryons from PBMCs cultured with
RANKL/M-CSF (left), with CM from untreated (middle) and Everolimus-treated (right) MCF-7 cells (scale bar: 30 μm; 30X magnification). b bottom:
images of TRAcP+ OC-like cells (scale bar: 35 μm; 20x magnification)
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of Everolimus to selectively target the m-TOR molecule
and hence inhibit the m-TOR-dependent p70S6K factor.
The inhibition of the interaction between the mTOR
and NFkB pathways exerted by Everolimus is shown in
Fig. 5 (middle) on both cell lines. IKKα and p65 exhibited
variably inhibited phosphorylated forms after Everolimus.
The effect was more pronounced for p-IKKα in MCF-7
cells, due to the higher constitutive expression of this fac-
tor. Similarly, M-CSF, IL-6, IL-1β, TNFα, and MIP-1α
were measured as NFkB-dependent factors. Figure 5
(below) shows their lowered intracellular content after
Everolimus, especially in MCF-7 cells, supporting the hy-
pothesized negative regulation of NFkB signaling by m-
TOR inhibition.
Everolimus-treated MDA-MB-231 cells reveal a restrained
osteolytic activity in SCID mice
Everolimus-treated and untreated MDA-MB-231 cells
were inoculated into the left and right tibia, respectively,
of each 8-week old SCID mouse. After 4 weeks, X-Rays
were taken to measure the extension of osteolytic areas.
We observed smaller osteolytic areas in the tibias
engrafted with treated MDA-MB-231 cells compared to
the contralateral tibias, that uniformly showed variably
enlarged proximal epiphyses due to the growth of meta-
static lesions. Figure 6a (left) illustrates a representative
X-Ray of a SCID mouse. As can be seen, the right tibia
injected with untreated MDA-MB-231 produced a larger
osteolytic lesion with blown cortical bone, compared to
the smaller lesion produced by Everolimus-treated cells
in the left tibia. Figure 6a (right) shows the average size
of these osteolytic areas measured on X-Ray films of all
mice, supporting the evidence of significantly larger
lesions in the right tibias, injected with untreated MDA-
MB231 cells (mean value: 1.7 ± 0.56 mm2) compared to
the left tibias, injected with Everolimus-treated cells
(0.9 ± 0.31 mm2) (p < 0.03). Finally, Fig. 6b and c shows
the histology pattern of tumor engraftment by MDA-
MB231 cells of the right tibia of a SCID mouse, displaying
devastation of the bone structure, massive infiltration of
the spongy bone, and a number of TRAcP+ cells, so func-
tional OCs, in close contact with the tumor cells and jux-
taposed to the cortical bone.
Discussion
Endocrine therapy is the standard care for patients with
advanced HR+ BC. However, after an initial response,
most patients develop endocrine resistance. The under-
lying molecular mechanism is PI3K/Akt/mTOR hyper-
activity, that drives the phosphorylation of the estrogen
receptor (ER) by p70S6K, leading to a ligand-independent
ER transcriptional activity. The involvement of mTOR in
the cell growth of endocrine resistant BC cells is also sup-
ported by the convergence of signaling from different
growth factor receptor pathways, such as the epidermal
growth factor receptor (EGFR), insulin growth factor re-
ceptor (IGF-1R) and insulin receptor (InsR), toward PI3K/
Akt/mTOR [38]. Moreover, besides the expected improve-
ment of progression-free survival obtained by mTOR
inhibition in Everolimus-treated patients with endocrine
resistant BC, results from the BOLERO-2 trial suggest that
this drug significantly delays skeletal disease progression,
exerting a definite bone-sparing effect in metastatic BC
patients [16].
Skeletal metastases occur in BC as an effect of the osteo-
tropism of this tumor, that primes OC hyperactivity to
Fig. 2 Effect of BC cells on the transcription of OC genes in PBMCs and inhibition by Everolimus. RNA levels of TRAcP, Cat-K, c-fms and RANK in
PBMCs after incubation with CM from BC cells, before and after treatment with Everolimus. Transcripts were variably increased in both cell lines,
particularly c-fms by MDA-MB-231, and significantly down-regulated by Everolimus. RNA levels were normalized to control OCs and to β-actin
levels as house-keeping gene, and expressed as 2-ΔΔCT
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generate typical osteolytic lesions. Although BC cells them-
selves are suspected to degrade the bone matrix [3], their
paracrine pro-OC activity is a major pathogenic event
driving excessive OC differentiation and hyperactivation,
resulting in the formation of bone metastases [39, 40].
Therefore, we investigated whether Everolimus acts as
a negative regulator of the paracrine pro-OC activity
of BC cells.
The beneficial effect of Everolimus on bone health in
the BOLERO-2 study has also been interpreted as a re-
sult of the inhibition of mTOR activity in OCs [16, 17].
It has been demonstrated in transgenic mice, bearing
human-TNFα to resemble a rheumatoid arthritis model,
that mTOR signaling drives OC function, and that in-
hibition of this pathway can mitigate bone erosion [41].
In these animals, mTOR inhibition by Everolimus or
Sirolimus resulted in a significantly decreased structural
damage in joints.
We used the BC cell lines MDA-MB-231 and MCF-7,
both capable of producing osteolytic lesions in animals
[36, 42]. In line with previous data [43], both cell lines
secreted variable amounts of pro-OC factors and their
CM accelerated the differentiation of PBMCs to TRAcP+
polykaryons, namely OCs showing bone-resorption ac-
tivity in vitro, with a concurrent RNA increase of pivotal
OC-related genes, such as RANK and c-fms as pheno-
type markers, and cathepsin-K and TRAcP as functional
markers.
Everolimus treatment of BC cells inhibited the release
of pro-OC factors. Using their CM, we observed a de-
cline in the formation of TRAcP+ polykaryons, together
with a lower transcription of major OC factors and
Fig. 3 Measurement of bone resorbing activity of OCs stimulated by BC cells. The OCs capacity to produce erosive lacunae on calcium phosphate
was measured after stimulation with CM from both untreated and Everolimus-treated BC cells. a Significant increases of the number of erosion pits
(above) and percentage of resorbed area (below), were observed after incubating OCs with CM from both BC cells, whereas this effect was significantly
suppressed by Everolimus (*p < 0.05). Results are means of three experiments. b Variation of erosive pit formation by von Kossa-staining of calcium
phosphate slices seeded with OCs compared to culture conditions. CM from Everolimus-treated MCF-7 cells inhibited the bone resorbing activity
(bottom, right) compared to the constitutive activity (above, right) and to untreated cells CM (bottom, left) (scale bar: 25 μm; 40x magnification)
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decreased bone resorbing ability. However, although
these effects were similarly detectable in both cell lines,
a higher inhibitory effect was recorded when PBMCs
were stimulated with CM from Everolimus-treated
MCF-7 cells. We interpreted this result as dependent on
the higher sensitivity to Everolimus treatment of MCF-7
cells, as an effect of the intrinsic PIK3CA deregulation
leading to a constitutive mTOR hyperactivity [44]. On
the other hand, in both cell lines the RNA of M-CSF,
TNFα, IL-1β, IL-6, MIP-1α and MMP-13, as major pro-
OC factors, was variably lowered by Everolimus: the
basal transcriptional profile implying a well-defined inher-
ited pro-OC potential was negatively regulated by the
mTOR inhibitor. However, transcriptional levels of other
genes such as RANK-L, MCP-1 and MMP-9 remained un-
detectable, as reported by other investigators [45].
A major result in our work was the inhibition of M-CSF,
IL-6, IL-1β, TNFα and MIP-1α induced by mTOR inhib-
ition. Constitutive phosphorylation of p70S6K, 4EBP1 and
eIF4E, as downstream mTOR effectors [46], has been de-
scribed to contribute to cell growth, angiogenesis and me-
tastasis in several tumors. mTOR inhibition restrains
these effects without having any apparent impact on M-
CSF, IL-6, and IL-1β secretion, since these factors are reg-
ulated by NFkB [20–24], whose activation is apparently
independent of the mTOR pathway. This point is dis-
puted, however, since previous works reported that a po-
tential interaction between mTOR and IKKα triggers
NFkB in tumor cells and constitutive activation of the
PI3K/Akt/mTOR pathway [25, 47]. We thus investigated
whether NFkB signaling is affected by mTOR. After treat-
ment of both cell lines with Everolimus, the secretion of
Fig. 4 Transcriptional and secretory profiles of pro-OC factors in Everolimus-treated BC cells. RNA levels of M-CSF, TNFα, IL-β, IL-6, MIP-1α and MMP-13
were variably suppressed in both MDA-MB-231 and MCF-7 cells after treatment with Everolimus. a RT-PCR showed a significant reduction of M-CSF,
TNFα, and MMP-13 RNAs in MDA-MB-231, with a concurrent diminution of IL-6. IL-1β, IL-6, MIP-1α and MMP13 were also significantly inhibited in MCF-7
cells as compared to normalized values from control untreated BC cells. Data are mean values from three experiments. b ELISA measurement of major
NFkB-dependent osteoclastogenic factors, namely M-CSF, IL-6, IL-1β, TNF-α and MIP-1α, released by cultured MDA-MB-231 and MCF-7 cells before or
after sub-lethal doses of Everolimus. In most instances, Everolimus suppressed the secretion of these factors (mean values from three experiments),
showing a similar pattern to that of RNA inhibition
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M-CSF, TNFα, IL-1β, IL-6 and MIP-1α in culture was sig-
nificantly reduced, in parallel with lower RNA values.
These data, together with the increased phosphorylated
levels of pIKKα and p-p65 at immunoblotting, support a
synergic down-regulation of both mTOR and NFkB. We
found, indeed, that higher levels of Akt, p-mTOR and
p-p70S6K in MCF-7 cells were correlated with simi-
larly increased levels of p-IKKα and p-p65 along the
NFkB pathway. The inhibition of NFkB phosphory-
lated effectors after treatment with Everolimus defin-
itely suggests a functional connection between the
mTOR and NFkB pathways.
It has been suggested that the functional disablement
of NFkB following proteasome inhibition may affect
intracellular signaling propagated through the mTOR
pathway [48]. In our study, however, we provide inverse
evidence that, at least in BC cells, both p-IKKα and p-
p65, as NFkB components, can be disabled by inhibiting
mTOR. Although it has been reported that both MDA-
MB-231 and MCF7 may acquire resistance to everolimus
[49], in our hands, the minor intracellular content of
pro-OC factors, namely M-CSF, IL-6, IL-1β, TNFα and
MIP-1α, induced by NFkB in Everolimus-treated BC
cells emphasizes the interactive negative regulation
Fig. 5 mTOR inhibition down-regulates the NFkB pathway in BC cells. Intracellular content of mTOR, NFkB-related molecules and pro-OC effectors in BC
cells before and after Everolimus treatment (measured by Western-blot). Protein lysates revealed a high native content, although at higher OD values in
MCF-7 cells, as in, Additioinal file 1: Table S2, of phosphorylated mTOR and p70S6K components of the mTOR pathway, and concurrently, p-IKKα and
p-p65 factors belonging to the NFkB signaling pathway. In both cell lines, Everolimus strongly suppressed the constitutive hyperphosphorylation of IKKα
and p65, as well as of p-mTOR and p-P70S6K. This supports the potential of Everolimus to inhibit the NFkB pathway, since the intracellular expression of
M-CSF, TNF-α, IL-6, IL-1β and MIP-1α, as major NFkB-dependent pro-OC factors, was suppressed as well as p-IKKα and p-p65. β-actin was the
loading control
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Fig. 7 Potential inhibitory interactions between the mTOR and NFkB pathways activated by Everolimus. It is suggestive that Everolimus disables
IKK by p-mTOR, thus restraining the phosphorylation of IKb. This event prevents the migration of p65, as NFkB component, to the nucleus where
it normally acts as transcription factor for M-CSF, TNF-α, IL-6, IL-1β and MIP-1α. This ultimately leads to an inhibited secretion of the pro-OC soluble
mediators coded by these genes
Fig. 6 Everolimus restrains the bone-metastatic potential of BC cells in vivo. Everolimus-treated and untreated MDA-MB-231 cells were intra-tibially
inoculated in 8-week old SCID mice. a X-Ray image of a representative SCID mouse after 4 weeks, showing blown cortical bone of the right tibia
and a smaller bone lesion produced by Everolimus-treated MDA-MB-231 cells in the left tibia. The graph shows levels of tibial erosion, measured by
ImageJ software. Data are expressed as mean ± SE of the 2D size of metastatic lesions (untreated MDA-MB-231: 1.7 ± 0.56 mm2; Everolimus-treated
MDA-MB-231: 0.9 ± 0.31 mm2; *p < 0.05). b Representative image of tumor infiltration in an excised tibia (H/E staining). The small box includes a
horizontal section of the right tibia, showing that the cortical bone is largely infiltrated by MDA-MB-231 cells, as revealed at higher magnitude. c
Detection of TRAcP+ cells at the tumor/bone interface of the same tibia
Simone et al. BMC Cancer  (2015) 15:692 Page 10 of 13
between these pathways. A model of interactive molecu-
lar cross-talk between mTOR and NFkB signaling is pro-
posed in Fig. 7.
To substantiate our hypothesis, we explored the effect
of mTOR inhibition on BC paracrine pro-OC activity in
a xenograft model of bone metastatic disease. In each
experiment, Everolimus-treated and untreated MDA-
MB-231 cells were intra-tibially injected into the left and
right tibial marrow cavity, respectively, of SCID mice.
This resulted in larger lytic lesions in the right than in
the left tibias. This in vivo experiment supported our hy-
pothesis that mTOR inhibition can inhibit the paracrine
activity of BC cells.
Therefore, besides the general anti-tumor activity ob-
tained by mTOR inhibition, the beneficial bone-sparing
result in the BOLERO-2 trial may be explained by at least
two effects. The first mechanism includes the known dir-
ect inhibition of OC activity [17, 41], while the second acts
through a negative regulation of the paracrine secre-
tion of pro-OC factors by BC cells. An additional
OC-independent effect is also related to the pro-osteoblast
activity of Everolimus, as recently reported [50]. The defin-
ite effect of mTOR inhibition on bone metastatic cancers
was recently explored in a collaborative review [51].
Finally, the potential of a sub-lethal dose of Everolimus
to abrogate the paracrine pro-OC activity of BC cells ac-
quires additional relevance when translated to the clin-
ical setting. In fact, in disseminated tumor cells (DTC)
PI3K/Akt signaling is reduced, thus suggesting that
mTOR pathway inhibition might be linked to a biologic
quiescence of DTC [52]. Thus, Everolimus at sub-lethal
dose alone, or in association with other treatments, may
delay or disable dormant bone metastatic disease by
freezing the tumor cells living in a quiescent state in
bone niches, which can generate metastases even after
long periods of apparent disease remission [53].
Conclusions
Two major points emerge from an analysis of our work.
The first is the capacity of Everolimus to restrain the
progression of skeletal metastatic disease in BC patients
through a specific mechanism that includes inhibiting
the release by these cells of the most effective pro-OC
factors such as M-CSF, TNFα, IL-1β, IL-6, MIP-1α and
MMP-13. The second point concerns the molecular
pathway activated in the release of several of these fac-
tors. M-CSF, IL-1β and IL-6 secretion is regulated both
in OCs and BC cells by the NFkB pathway, whose sig-
naling is apparently independent of mTOR. Instead, here
we provide evidence that these pathways are intercon-
nected and that the inhibitory effects on mTOR exerted
by Everolimus include a negative regulation of NFkB,
thus explaining the reduced secretion of M-CSF, IL-1β
and IL-6 by BC cells after mTOR inhibition. Therefore,
the beneficial effects of Everolimus on bone health re-
ported in the BOLERO-2 trial are related to the inhib-
ition of the pro-OC paracrine activity of BC cells. To
our knowledge, this is the first report describing this
specific effect of the mTOR inhibitor.
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